College Station, TX and Port Washington, NY – September 25, 2018: G-CON Manufacturing, the leader in prefabricated, prequalified cleanroom solutions, and Pall Corporation, a global leader in filtration, separation and purification, are collaborating to bring turnkey continuous bioprocess or viral vector production facility solutions to the industry. G-CON PODs will be customized with advanced Pall Biotech bioprocess equipment, including automation and utility supplies; these will be predesigned into the G-CON cleanroom units for scalable deployment.
 

“Together, Pall’s cutting-edge technology and G-CON’s flexible cleanroom platform take the concept of modularity one step further, delivering a complete, reproducible, scalable facility solution that is easy to place or relocate, as well as clean, sanitize and even repurpose,” said Mario Philips, Vice President & General Manager at Pall Biotech. “This strategic collaboration is particularly important to Pall, as we continuously improve bioprocesses for the industry by offering innovative solutions like G-CON PODs customized with Pall technologies. This solution addresses customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing.”
 

PODs from G-CON are mobile, and include integrated process piping and heating and air conditioning (HVAC) systems. Deploying the customized PODs is simple by design, allowing a customer to focus on the target molecule, while relying on the G-CON and Pall teams to optimize the facility design and process. Once designed, the PODs ease verification, qualification and validation challenges by providing comprehensive site acceptance testing and even IQ/OQ support. The PODs’ flexibility allows them to support multiple products, and they can be easily repurposed. In addition, the cost of “building” a facility is drastically reduced, as is build time, which increases the return on investment.
 

“G-CON’s prefabricated cleanroom units feature a complete, yet compressed footprint for Pall’s continuous bioprocessing and viral vector production designs. The implementation of the Pall processes into our POD infrastructure creates an ideal turnkey solution for our customers. These solutions will be readily deployable and scalable, as they reduce the typical design, verification and qualification efforts by standardizing processes and cleanroom environments,” said Maik Jornitz, President and CEO of G-CON Manufacturing. “We are looking forward to combining our PODs with Pall’s process knowledge and designs to serve our joint customer base. The industry requires optimized, fast, scalable solutions, and these requirements will be met through this collaboration.”
 

Engineering teams from G-CON and Pall will align to design and deliver the mobile, prefabricated cleanroom units to meet individual customer needs. Process solutions will also be addressed in response to customer needs and applications. Both companies will continue to offer their products and services independently, in addition to the collaboration.

Drawing: Continuous PD Bioprocessing
Drawing: Viral Vector Platform
 

About G-CON

G-CON Manufacturing designs, produces and installs prefabricated cleanroom PODs®. G-CON’s cleanroom POD portfolio provides a variety of dimensions and serves multiple purposes, from laboratory environments to personalized medicine and production process platforms. POD cleanroom units are unique among traditional cleanroom structures in terms of scalability, mobility and the ability to repurpose the PODs once the production process reaches the end of its lifecycle. For more information, please visit the Company's website at www.gconbio.com or follow us on social media via LinkedIn, Twitter, YouTube, Instagram and Facebook.
 

About Pall Corporation

Pall Corporation is a filtration, separation and purification leader, providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.
 

For more information visit www.pall.com. Or follow us on social media: YouTube - LinkedIn - Twitter - Facebook

 

For more information:

 

G-CON Media Contact

Brittany Berryman

Director of Marketing

G-CON Manufacturing, Inc.

6161 Imperial Loop, College Station, TX 77845

Phone: 979-204-7975

e-mail: bberryman@gconbio.com

www.gconbio.com

 

Pall Corporate Media Contact

Mariann Kourafas

Director of Communications

Pall Corporation

Phone: +1-508-871-5469

www.pall.com

               

Pall Biotech Media Contact

White Matter Communications

Beth Willers

bethw@whitemattercomm.com

+1-415-905-0324

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development
September 3, 2018: Celltheon and Pall to provide an integrated, cost-effective, time efficient end-to-end solution for research and bioproduction to expedite drug development and provide solutions for unmet needs in bioprocessing